January 4, 2021
Informed Consent Is Compulsory
Because every medical treatment must be administered following an informed consent,
Because the massive and unlawful advertising in the mainstream media says nothing beyond “get vaccinated”,
Because only you must decide what you do with your own body, and it is you again who decide whether medical treatments will be applied to your children,
I shall leave you below a link to the official leaflet which informs you summarily and minimally about what you need to know concerning the “concentrate for dispersion for injection” COMIRNATY — the name borne by the Pfizer COVID-19 mRNA Vaccine (nucleoside-modified) which the “authorities” urge you to take.
At the same time I propose that you bear in mind in particular the following points, which we find in the Pfizer leaflet:
“- The safety and efficacy of Comirnaty in children and adolescents under 16 years of age have not yet been established.
- Hypersensitivity and anaphylaxis
Events of anaphylaxis have been reported. Appropriate medical treatment and supervision must always be readily available in case of an anaphylactic reaction following administration of the vaccine.
Close observation for at least 15 minutes is recommended following vaccination. A second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Comirnaty.
- Anxiety-related reactions
Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
- Concurrent illness
Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
- Thrombocytopenia and coagulation disorders
As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
- Immunocompromised individuals
The efficacy, safety and immunogenicity of the vaccine have not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of Comirnaty may be lower in immunosuppressed individuals.
- Duration of protection
The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials.
- Limitations of vaccine effectiveness
As with any vaccine, vaccination with Comirnaty may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of the vaccine.
- Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
- Pregnancy
There is limited experience with the use of Comirnaty in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see section 5.3). Administration of Comirnaty in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
- Breast-feeding
It is unknown whether Comirnaty is excreted in human milk.
- Fertility
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
- In participants 16 years of age and older, the most frequent adverse reactions were injection site pain (>80%), fatigue (>60%), headache (>50%), myalgia and chills (>30%), arthralgia (>20%), pyrexia and injection site swelling (>10%), and these were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.
-†Throughout the safety follow-up period to date, acute peripheral facial paralysis was reported by four participants in the COVID-19 mRNA vaccine group. The facial paralysis began on Day 37 after Dose 1 (the participant did not receive Dose 2) and on Days 3, 9 and 48 after Dose 2. No cases of acute peripheral facial paralysis were reported in the placebo group.”
“If I have already had COVID-19 and recovered, do I still need to be vaccinated?
At present there is not enough information about how long, after infection, the person concerned is protected from contracting the disease again. Initial studies have shown that immunity to COVID-19 will not last very long, but further studies are needed for this aspect to be better understood. Consequently, at this moment the CDC has no position regarding the vaccination of patients who have already had the disease.”
For all the unknowns and ambiguities listed above and in the attached leaflet,
I SHALL NOT BE VACCINATED!
Please read, inform yourselves and decide for yourselves!
https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_ro.pdf
See the post on FacebookThe Facebook archive keeps no permanent addresses for posts. The link above is rebuilt from the identifier of the attached photograph, and some posts are no longer public — Facebook has deleted, restricted or moved them — so it may answer “This page isn’t available”. If that happens, search for the post by its text on the author’s page.
Comments
Have your say. Comments appear once approved.